229 related articles for article (PubMed ID: 12550042)
21. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
Aktaş G; Bozdoğan B; Derbentli S
Mikrobiyol Bul; 2012 Jul; 46(3):359-65. PubMed ID: 22951648
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods.
Tubau F; Fernández-Roblas R; Liñares J; Martín R; Soriano F
J Antimicrob Chemother; 2001 May; 47(5):675-80. PubMed ID: 11328783
[TBL] [Abstract][Full Text] [Related]
23. Linezolid.
Narang M; Gomber S
Indian Pediatr; 2004 Nov; 41(11):1129-32. PubMed ID: 15591662
[TBL] [Abstract][Full Text] [Related]
24. Use of linezolid in children: an overview of recent advances.
Velissariou IM
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):947-52. PubMed ID: 17181410
[TBL] [Abstract][Full Text] [Related]
25. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
Andes D; van Ogtrop ML; Peng J; Craig WA
Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
[TBL] [Abstract][Full Text] [Related]
26. [The role of linezolid in the therapy of infections caused by multiresistant gram-positive cocci].
Paradisi F; Corti G
Infez Med; 2004 Mar; 12(1):19-26. PubMed ID: 15329525
[TBL] [Abstract][Full Text] [Related]
27. The oxazolidinones as a new family of antimicrobial agent.
Marchese A; Schito GC
Clin Microbiol Infect; 2001; 7 Suppl 4():66-74. PubMed ID: 11688536
[TBL] [Abstract][Full Text] [Related]
28. Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections.
Bassetti M; Farrel PA; Callan DA; Topal JE; Dembry LM
Int J Antimicrob Agents; 2003 Jun; 21(6):593-4. PubMed ID: 12791477
[No Abstract] [Full Text] [Related]
29. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
30. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: emerging problems and new prospects for management.
Noskin GA
Ann Acad Med Singap; 2001 May; 30(3):320-31. PubMed ID: 11455748
[TBL] [Abstract][Full Text] [Related]
31. Linezolid - the first oxazolidinone in the treatment of nosocomial MRSA pneumonia.
Burkhardt O; Pletz MW; Mertgen CP; Welte T
Recent Pat Antiinfect Drug Discov; 2007 Jun; 2(2):123-30. PubMed ID: 18221168
[TBL] [Abstract][Full Text] [Related]
32. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.
Noskin GA; Siddiqui F; Stosor V; Hacek D; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2059-62. PubMed ID: 10428937
[TBL] [Abstract][Full Text] [Related]
33. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.
Seedat J; Zick G; Klare I; Konstabel C; Weiler N; Sahly H
Antimicrob Agents Chemother; 2006 Dec; 50(12):4217-9. PubMed ID: 16982791
[TBL] [Abstract][Full Text] [Related]
34. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
[TBL] [Abstract][Full Text] [Related]
35. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe).
Bolmstrom A; Ballow CH; Qwarnstrom A; Biedenbach DJ; Jones RN
Clin Microbiol Infect; 2002 Dec; 8(12):791-800. PubMed ID: 12519352
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group.
Henwood CJ; Livermore DM; Johnson AP; James D; Warner M; Gardiner A
J Antimicrob Chemother; 2000 Dec; 46(6):931-40. PubMed ID: 11102412
[TBL] [Abstract][Full Text] [Related]
37. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.
Falagas ME; Vardakas KZ
Drug Saf; 2008; 31(9):753-68. PubMed ID: 18707190
[TBL] [Abstract][Full Text] [Related]
38. Linezolid resistance in a clinical isolate of Staphylococcus aureus.
Tsiodras S; Gold HS; Sakoulas G; Eliopoulos GM; Wennersten C; Venkataraman L; Moellering RC; Ferraro MJ
Lancet; 2001 Jul; 358(9277):207-8. PubMed ID: 11476839
[TBL] [Abstract][Full Text] [Related]
39. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.
Swoboda S; Fritz S; Martignoni ME; Feldhues RA; Hoppe-Tichy T; Buchler MW; Geiss HK
J Antimicrob Chemother; 2005 Oct; 56(4):787-9. PubMed ID: 16143710
[TBL] [Abstract][Full Text] [Related]
40. Linezolid in children: recent patents and advances.
Velissariou IM
Recent Pat Antiinfect Drug Discov; 2007 Jan; 2(1):73-7. PubMed ID: 18221164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
